Guardant Health (NASDAQ:GH – Get Free Report) had its price target dropped by analysts at The Goldman Sachs Group from $43.00 to $37.00 in a report issued on Monday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. The Goldman Sachs Group’s target price would suggest a potential upside of 57.18% from the stock’s current price.
A number of other equities analysts have also issued reports on the stock. Guggenheim began coverage on shares of Guardant Health in a research report on Thursday, December 14th. They set a “neutral” rating for the company. Morgan Stanley dropped their price objective on shares of Guardant Health from $55.00 to $50.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 8th. Raymond James raised shares of Guardant Health from a “market perform” rating to an “outperform” rating and set a $27.00 price objective on the stock in a research note on Monday, November 13th. Wolfe Research began coverage on shares of Guardant Health in a research note on Wednesday, December 13th. They set a “peer perform” rating on the stock. Finally, Citigroup reaffirmed a “buy” rating and set a $50.00 price objective on shares of Guardant Health in a research note on Monday, October 2nd. Two research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, Guardant Health presently has a consensus rating of “Moderate Buy” and a consensus target price of $48.00.
Read Our Latest Report on Guardant Health
Guardant Health Trading Up 1.9 %
Shares of NASDAQ GH traded up $0.44 during mid-day trading on Monday, reaching $23.54. The company had a trading volume of 166,547 shares, compared to its average volume of 1,477,626. The business’s 50-day moving average is $25.62 and its 200-day moving average is $29.48. The company has a current ratio of 5.94, a quick ratio of 5.60 and a debt-to-equity ratio of 4.99. The stock has a market cap of $2.78 billion, a price-to-earnings ratio of -5.79 and a beta of 0.99. Guardant Health has a 52 week low of $20.67 and a 52 week high of $41.06.
Guardant Health (NASDAQ:GH – Get Free Report) last issued its earnings results on Monday, November 6th. The company reported ($0.73) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.93) by $0.20. Guardant Health had a negative net margin of 80.69% and a negative return on equity of 322.25%. The company had revenue of $143.03 million for the quarter, compared to analysts’ expectations of $137.25 million. Equities analysts expect that Guardant Health will post -3.59 earnings per share for the current year.
Insider Activity at Guardant Health
In other news, insider Kumud Kalia sold 5,800 shares of the business’s stock in a transaction dated Friday, December 1st. The stock was sold at an average price of $26.37, for a total transaction of $152,946.00. Following the completion of the transaction, the insider now directly owns 5,926 shares of the company’s stock, valued at $156,268.62. The sale was disclosed in a filing with the SEC, which is accessible through this link. 6.20% of the stock is owned by insiders.
Hedge Funds Weigh In On Guardant Health
A number of institutional investors and hedge funds have recently added to or reduced their stakes in GH. US Bancorp DE raised its position in Guardant Health by 5.2% in the first quarter. US Bancorp DE now owns 12,808 shares of the company’s stock worth $849,000 after acquiring an additional 632 shares in the last quarter. MetLife Investment Management LLC acquired a new stake in Guardant Health in the first quarter valued at $385,000. Vontobel Holding Ltd. grew its holdings in Guardant Health by 20.3% in the first quarter. Vontobel Holding Ltd. now owns 16,548 shares of the company’s stock valued at $1,109,000 after purchasing an additional 2,797 shares during the last quarter. Bridgewater Associates LP grew its holdings in Guardant Health by 36.0% in the first quarter. Bridgewater Associates LP now owns 143,041 shares of the company’s stock valued at $9,475,000 after purchasing an additional 37,888 shares during the last quarter. Finally, First Trust Advisors LP grew its holdings in Guardant Health by 186.3% in the first quarter. First Trust Advisors LP now owns 24,392 shares of the company’s stock valued at $1,616,000 after purchasing an additional 15,873 shares during the last quarter. 92.65% of the stock is owned by institutional investors and hedge funds.
Guardant Health Company Profile
Guardant Health, Inc, a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360; Guardant360 LDT; Guardant360 CDx; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Guardant Health, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Guardant Health wasn’t on the list.
While Guardant Health currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Source: marketbeat.com
